Kristin Palmsten1, Katrina F Flores2, Christina D Chambers1,2, Lauren A Weiss3, Rajeshwari Sundaram4, Germaine M Buck Louis4. 1. 1 Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA. 2. 2 Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, USA. 3. 3 Department of Medicine, University of California, San Diego, La Jolla, CA, USA. 4. 4 Division of Intramural Population Health Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Rockville, MD, USA.
Abstract
OBJECTIVE: To identify frequently reported prescription medications and supplements among couples planning pregnancy because there is a lack of descriptive information on these agents in women and men who are trying to conceive. METHODS: Five hundred one couples enrolled in the Longitudinal Study of Infertility and the Environment, which took place between 2005 and 2009. Participants reported prescription medications as well as prescription and over-the-counter supplements used through interviews at study enrollment and through daily dairies during the 12-month follow-up. We identified prescription medications and supplements prospectively reported by ≥1% of women and men at baseline and from daily journal information grouped into 3-month preconception follow-up intervals while couples tried for pregnancy. RESULTS: The 5 most reported prescription medications among women were levothyroxine (5.8%), cetirizine (2.6%), fluticasone (2.4%), escitalopram (1.8%), and fluoxetine (1.8%) and for men were lisinopril (2.0%), mometasone (2.0%), fexofenadine (1.8%), atorvastatin (1.6%), and montelukast (1.6%). The most reported supplements were multivitamins (63.3%, 43.5%) and fish oil (13.2%, 9.4%) for women and men, respectively, and prenatal vitamins (22.0%) for women. For women during the first 3 months of follow-up, prenatal vitamins (6.0%) and antibiotics (1.2%-2.6%) were among the most frequently started medications. During the next 3 months, clomiphene (4.5%) was the most frequently initiated medication. CONCLUSIONS: Couples trying for pregnancy reported a variety of prescription medications and supplements, and they differed by gender. Preconception guidance should address medication and supplement use to avoid potential exposures associated with adverse reproductive and perinatal outcomes.
OBJECTIVE: To identify frequently reported prescription medications and supplements among couples planning pregnancy because there is a lack of descriptive information on these agents in women and men who are trying to conceive. METHODS: Five hundred one couples enrolled in the Longitudinal Study of Infertility and the Environment, which took place between 2005 and 2009. Participants reported prescription medications as well as prescription and over-the-counter supplements used through interviews at study enrollment and through daily dairies during the 12-month follow-up. We identified prescription medications and supplements prospectively reported by ≥1% of women and men at baseline and from daily journal information grouped into 3-month preconception follow-up intervals while couples tried for pregnancy. RESULTS: The 5 most reported prescription medications among women were levothyroxine (5.8%), cetirizine (2.6%), fluticasone (2.4%), escitalopram (1.8%), and fluoxetine (1.8%) and for men were lisinopril (2.0%), mometasone (2.0%), fexofenadine (1.8%), atorvastatin (1.6%), and montelukast (1.6%). The most reported supplements were multivitamins (63.3%, 43.5%) and fish oil (13.2%, 9.4%) for women and men, respectively, and prenatal vitamins (22.0%) for women. For women during the first 3 months of follow-up, prenatal vitamins (6.0%) and antibiotics (1.2%-2.6%) were among the most frequently started medications. During the next 3 months, clomiphene (4.5%) was the most frequently initiated medication. CONCLUSIONS: Couples trying for pregnancy reported a variety of prescription medications and supplements, and they differed by gender. Preconception guidance should address medication and supplement use to avoid potential exposures associated with adverse reproductive and perinatal outcomes.
Entities:
Keywords:
dietary supplements; fecundity; fertility; medication; preconception care
Authors: Germaine M Buck Louis; Katherine J Sapra; Enrique F Schisterman; Courtney D Lynch; José M Maisog; Katherine L Grantz; Rajeshwari Sundaram Journal: Fertil Steril Date: 2016-03-22 Impact factor: 7.329
Authors: Kristin Palmsten; Sonia Hernández-Díaz; Christina D Chambers; Helen Mogun; Sophia Lai; Todd P Gilmer; Krista F Huybrechts Journal: Obstet Gynecol Date: 2015-09 Impact factor: 7.661
Authors: April L Dawson; Elizabeth C Ailes; Suzanne M Gilboa; Regina M Simeone; Jennifer N Lind; Sherry L Farr; Cheryl S Broussard; Jennita Reefhuis; Gerrard Carrino; Janis Biermann; Margaret A Honein Journal: MMWR Morb Mortal Wkly Rep Date: 2016-01-29 Impact factor: 17.586
Authors: Brian T Bateman; Sonia Hernandez-Diaz; Michael A Fischer; Ellen W Seely; Jeffrey L Ecker; Jessica M Franklin; Rishi J Desai; Cora Allen-Coleman; Helen Mogun; Jerry Avorn; Krista F Huybrechts Journal: BMJ Date: 2015-03-17
Authors: Jessica L Bauer; Katherine Kuhn; Andrew P Bradford; Zain A Al-Safi; Mary A Harris; Robert H Eckel; Celeste Y Robledo; Anahit Malkhasyan; Joshua Johnson; Nancy R Gee; Alex J Polotsky Journal: Reprod Sci Date: 2019-02-17 Impact factor: 3.060
Authors: Enrique F Schisterman; Lindsey A Sjaarda; Traci Clemons; Douglas T Carrell; Neil J Perkins; Erica Johnstone; Denise Lamb; Kayla Chaney; Bradley J Van Voorhis; Ginny Ryan; Karen Summers; Jim Hotaling; Jared Robins; James L Mills; Pauline Mendola; Zhen Chen; Elizabeth A DeVilbiss; C Matthew Peterson; Sunni L Mumford Journal: JAMA Date: 2020-01-07 Impact factor: 56.272
Authors: Tommy Jiang; Vadim Osadchiy; Alvaro Santamaria; Michael H Zheng; Neilufar Modiri; John T Sigalos; Keith V Regets; Jesse N Mills; Sriram V Eleswarapu Journal: Transl Androl Urol Date: 2022-02
Authors: Lindsay D Levine; Keewan Kim; Alexandra Purdue-Smithe; Rajeshwari Sundaram; Enrique F Schisterman; Matthew Connell; Elizabeth A Devilbiss; Zeina Alkhalaf; Jeannie G Radoc; Germaine M Buck Louis; Sunni L Mumford Journal: J Endocr Soc Date: 2019-12-05